Last reviewed · How we verify
CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells is a Biologic drug developed by Sorrento Therapeutics, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | CAR2 Anti-CD38 A2 CAR-T Cells |
|---|---|
| Sponsor | Sorrento Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAR2 Anti-CD38 A2 CAR-T Cells CI brief — competitive landscape report
- CAR2 Anti-CD38 A2 CAR-T Cells updates RSS · CI watch RSS
- Sorrento Therapeutics, Inc. portfolio CI
Frequently asked questions about CAR2 Anti-CD38 A2 CAR-T Cells
What is CAR2 Anti-CD38 A2 CAR-T Cells?
CAR2 Anti-CD38 A2 CAR-T Cells is a Biologic drug developed by Sorrento Therapeutics, Inc..
Who makes CAR2 Anti-CD38 A2 CAR-T Cells?
CAR2 Anti-CD38 A2 CAR-T Cells is developed by Sorrento Therapeutics, Inc. (see full Sorrento Therapeutics, Inc. pipeline at /company/sorrento-therapeutics-inc).
What development phase is CAR2 Anti-CD38 A2 CAR-T Cells in?
CAR2 Anti-CD38 A2 CAR-T Cells is in Phase 1.